X4 Pharma raises $60M, CEO and CFO resign, new leadership team appointed

X4 Pharmaceuticals, Inc

Private placement of 11,040,776 shares at $1.42/share and pre-funded warrants for 31,234,731 shares for ~$60M gross.
CEO Paula Ragan, Ph.D., and CFO Adam S. Mostafa resigned effective Aug 12, 2025; no disagreement cited.
Adam Raymond Craig, M.D., Ph.D., appointed Executive Chairman and principal executive officer; John Volpone named President.
David H. Kirske appointed CFO, Secretary, principal financial and accounting officer.
Proceeds to fund continued development of mavorixafor for chronic neutropenia and commercialization for WHIM.

item 1.01item 3.02item 5.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.